An Open Label, Multicenter, Phase II Study to Evaluate Efficacy and Safety of the BiTE Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Latest Information Update: 28 Feb 2023
Price :
$35 *
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 24 Feb 2023 Results of pooled analysis (n=683) assessing the association between bBMB% and treatment outcomes in relapsed/refractory (R/R) B-acute lymphoblastic leukemia from 5 trials (NCT01209286, NCT01466179, NCT01471782, NCT02013167, NCT02187354), published in the Cancer.
- 03 Nov 2020 Results (n=259) of pooled analysis from two clinical trials: NCT01209286 and NCT01466179 assessing long-term relapsed free survival and Overall survival published in the Cancer
- 02 Nov 2019 Results published in the Clinical Pharmacokinetics